Can the Hims & Hers GLP-1 partnership with Novo Nordisk turn telehealth weight loss into the company’s next major growth engine? Maik Kemper Editor in…
Are Hims & Hers insider transactions hinting at caution just as the company doubles down on its high-stakes GLP-1 obesity strategy? Maik Kemper Editor-in-Chief Conclusion…
Can the new Hims & Hers Novo Nordisk deal really turn an 80% stock collapse into a long-term GLP-1 comeback story? How big is the…
Hims & Hers quarter shows strong growth but weak outlook, GLP-1 dispute, and SEC risks – what this means for investors.
Real-time news feed for HIMS is coming soon.
Check back for live market news and analyst updates.